Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
Identifieur interne : 003627 ( PubMed/Curation ); précédent : 003626; suivant : 003628Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
Auteurs : B. Escudier [France] ; M D Michaelson [États-Unis] ; R J Motzer [États-Unis] ; T E Hutson [États-Unis] ; J I Clark [États-Unis] ; H Y Lim [Corée du Sud] ; E. Porfiri [Royaume-Uni] ; P. Zalewski [Canada] ; G. Kannourakis [Australie] ; M. Staehler [Allemagne] ; J. Tarazi [États-Unis] ; B. Rosbrook [États-Unis] ; L. Cisar [États-Unis] ; S. Hariharan [États-Unis] ; S. Kim [États-Unis] ; B I Rini [États-Unis]Source :
- British journal of cancer [ 1532-1827 ] ; 2014.
Descripteurs français
- KwdFr :
- Antinéoplasiques (effets indésirables), Antinéoplasiques (usage thérapeutique), Charge tumorale, Cytokines (usage thérapeutique), Humains, Imidazoles (effets indésirables), Imidazoles (usage thérapeutique), Indazoles (effets indésirables), Indazoles (usage thérapeutique), Indoles (usage thérapeutique), Inhibiteurs de protéines kinases (effets indésirables), Inhibiteurs de protéines kinases (usage thérapeutique), Nicotinamide (analogues et dérivés), Nicotinamide (effets indésirables), Nicotinamide (usage thérapeutique), Néphrocarcinome (anatomopathologie), Néphrocarcinome (mortalité), Néphrocarcinome (traitement médicamenteux), Phénylurées (effets indésirables), Phénylurées (usage thérapeutique), Pyrroles (usage thérapeutique), Résultat thérapeutique, Survie sans rechute, Tumeurs du rein (anatomopathologie), Tumeurs du rein (mortalité), Tumeurs du rein (traitement médicamenteux).
- MESH :
- analogues et dérivés : Nicotinamide.
- anatomopathologie : Néphrocarcinome, Tumeurs du rein.
- effets indésirables : Antinéoplasiques, Imidazoles, Indazoles, Inhibiteurs de protéines kinases, Nicotinamide, Phénylurées.
- mortalité : Néphrocarcinome, Tumeurs du rein.
- traitement médicamenteux : Néphrocarcinome, Tumeurs du rein.
- usage thérapeutique : Antinéoplasiques, Cytokines, Imidazoles, Indazoles, Indoles, Inhibiteurs de protéines kinases, Nicotinamide, Phénylurées, Pyrroles.
- Charge tumorale, Humains, Résultat thérapeutique, Survie sans rechute.
English descriptors
- KwdEn :
- Antineoplastic Agents (adverse effects), Antineoplastic Agents (therapeutic use), Carcinoma, Renal Cell (drug therapy), Carcinoma, Renal Cell (mortality), Carcinoma, Renal Cell (pathology), Cytokines (therapeutic use), Disease-Free Survival, Humans, Imidazoles (adverse effects), Imidazoles (therapeutic use), Indazoles (adverse effects), Indazoles (therapeutic use), Indoles (therapeutic use), Kidney Neoplasms (drug therapy), Kidney Neoplasms (mortality), Kidney Neoplasms (pathology), Niacinamide (adverse effects), Niacinamide (analogs & derivatives), Niacinamide (therapeutic use), Phenylurea Compounds (adverse effects), Phenylurea Compounds (therapeutic use), Protein Kinase Inhibitors (adverse effects), Protein Kinase Inhibitors (therapeutic use), Pyrroles (therapeutic use), Treatment Outcome, Tumor Burden.
- MESH :
- chemical , adverse effects : Antineoplastic Agents, Imidazoles, Indazoles, Niacinamide, Phenylurea Compounds, Protein Kinase Inhibitors.
- chemical , analogs & derivatives : Niacinamide.
- chemical , therapeutic use : Antineoplastic Agents, Cytokines, Imidazoles, Indazoles, Indoles, Niacinamide, Phenylurea Compounds, Protein Kinase Inhibitors, Pyrroles.
- drug therapy : Carcinoma, Renal Cell, Kidney Neoplasms.
- mortality : Carcinoma, Renal Cell, Kidney Neoplasms.
- pathology : Carcinoma, Renal Cell, Kidney Neoplasms.
- Disease-Free Survival, Humans, Treatment Outcome, Tumor Burden.
Abstract
In the AXIS trial, axitinib prolonged progression-free survival (PFS) vs sorafenib in patients with advanced renal cell carcinoma (RCC) previously treated with sunitinib or cytokines.
DOI: 10.1038/bjc.2014.244
PubMed: 24823696
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003741
Links to Exploration step
pubmed:24823696Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.</title><author><name sortKey="Escudier, B" sort="Escudier, B" uniqKey="Escudier B" first="B" last="Escudier">B. Escudier</name><affiliation wicri:level="1"><nlm:affiliation>Institut Gustave Roussy/Medical Oncology Department, Villejuif 94805, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Gustave Roussy/Medical Oncology Department, Villejuif 94805</wicri:regionArea></affiliation></author><author><name sortKey="Michaelson, M D" sort="Michaelson, M D" uniqKey="Michaelson M" first="M D" last="Michaelson">M D Michaelson</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA 02114</wicri:regionArea></affiliation></author><author><name sortKey="Motzer, R J" sort="Motzer, R J" uniqKey="Motzer R" first="R J" last="Motzer">R J Motzer</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021</wicri:regionArea></affiliation></author><author><name sortKey="Hutson, T E" sort="Hutson, T E" uniqKey="Hutson T" first="T E" last="Hutson">T E Hutson</name><affiliation wicri:level="1"><nlm:affiliation>Baylor-Sammons/Texas Oncology Physician's Association, Sammons Cancer Center, Dallas, TX 75246, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Baylor-Sammons/Texas Oncology Physician's Association, Sammons Cancer Center, Dallas, TX 75246</wicri:regionArea></affiliation></author><author><name sortKey="Clark, J I" sort="Clark, J I" uniqKey="Clark J" first="J I" last="Clark">J I Clark</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL 60153, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL 60153</wicri:regionArea></affiliation></author><author><name sortKey="Lim, H Y" sort="Lim, H Y" uniqKey="Lim H" first="H Y" last="Lim">H Y Lim</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, Samsung Medical Center/Sungkyunkwan University, Seoul 135-710, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Internal Medicine, Samsung Medical Center/Sungkyunkwan University, Seoul 135-710</wicri:regionArea></affiliation></author><author><name sortKey="Porfiri, E" sort="Porfiri, E" uniqKey="Porfiri E" first="E" last="Porfiri">E. Porfiri</name><affiliation wicri:level="1"><nlm:affiliation>Queen Elizabeth Hospital Birmingham, Birmingham B15 2WB, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Queen Elizabeth Hospital Birmingham, Birmingham B15 2WB</wicri:regionArea></affiliation></author><author><name sortKey="Zalewski, P" sort="Zalewski, P" uniqKey="Zalewski P" first="P" last="Zalewski">P. Zalewski</name><affiliation wicri:level="1"><nlm:affiliation>Durham Regional Cancer Centre, Oshawa, Ontario L1G 2B9, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Durham Regional Cancer Centre, Oshawa, Ontario L1G 2B9</wicri:regionArea></affiliation></author><author><name sortKey="Kannourakis, G" sort="Kannourakis, G" uniqKey="Kannourakis G" first="G" last="Kannourakis">G. Kannourakis</name><affiliation wicri:level="1"><nlm:affiliation>Fiona Elsey Cancer Research Institute and Ballarat Oncology and Haematology Services, Ballarat, Victoria 3355, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Fiona Elsey Cancer Research Institute and Ballarat Oncology and Haematology Services, Ballarat, Victoria 3355</wicri:regionArea></affiliation></author><author><name sortKey="Staehler, M" sort="Staehler, M" uniqKey="Staehler M" first="M" last="Staehler">M. Staehler</name><affiliation wicri:level="1"><nlm:affiliation>Ludwig-Maximilians University of Munich, Munich 80539, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Ludwig-Maximilians University of Munich, Munich 80539</wicri:regionArea></affiliation></author><author><name sortKey="Tarazi, J" sort="Tarazi, J" uniqKey="Tarazi J" first="J" last="Tarazi">J. Tarazi</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Oncology, San Diego, CA 92121, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, San Diego, CA 92121</wicri:regionArea></affiliation></author><author><name sortKey="Rosbrook, B" sort="Rosbrook, B" uniqKey="Rosbrook B" first="B" last="Rosbrook">B. Rosbrook</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Oncology, San Diego, CA 92121, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, San Diego, CA 92121</wicri:regionArea></affiliation></author><author><name sortKey="Cisar, L" sort="Cisar, L" uniqKey="Cisar L" first="L" last="Cisar">L. Cisar</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Oncology, New York, NY 10017, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, New York, NY 10017</wicri:regionArea></affiliation></author><author><name sortKey="Hariharan, S" sort="Hariharan, S" uniqKey="Hariharan S" first="S" last="Hariharan">S. Hariharan</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Oncology, New York, NY 10017, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, New York, NY 10017</wicri:regionArea></affiliation></author><author><name sortKey="Kim, S" sort="Kim, S" uniqKey="Kim S" first="S" last="Kim">S. Kim</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Oncology, San Diego, CA 92121, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, San Diego, CA 92121</wicri:regionArea></affiliation></author><author><name sortKey="Rini, B I" sort="Rini, B I" uniqKey="Rini B" first="B I" last="Rini">B I Rini</name><affiliation wicri:level="1"><nlm:affiliation>Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24823696</idno><idno type="pmid">24823696</idno><idno type="doi">10.1038/bjc.2014.244</idno><idno type="wicri:Area/PubMed/Corpus">003741</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003741</idno><idno type="wicri:Area/PubMed/Curation">003627</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003627</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.</title><author><name sortKey="Escudier, B" sort="Escudier, B" uniqKey="Escudier B" first="B" last="Escudier">B. Escudier</name><affiliation wicri:level="1"><nlm:affiliation>Institut Gustave Roussy/Medical Oncology Department, Villejuif 94805, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Gustave Roussy/Medical Oncology Department, Villejuif 94805</wicri:regionArea></affiliation></author><author><name sortKey="Michaelson, M D" sort="Michaelson, M D" uniqKey="Michaelson M" first="M D" last="Michaelson">M D Michaelson</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA 02114</wicri:regionArea></affiliation></author><author><name sortKey="Motzer, R J" sort="Motzer, R J" uniqKey="Motzer R" first="R J" last="Motzer">R J Motzer</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021</wicri:regionArea></affiliation></author><author><name sortKey="Hutson, T E" sort="Hutson, T E" uniqKey="Hutson T" first="T E" last="Hutson">T E Hutson</name><affiliation wicri:level="1"><nlm:affiliation>Baylor-Sammons/Texas Oncology Physician's Association, Sammons Cancer Center, Dallas, TX 75246, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Baylor-Sammons/Texas Oncology Physician's Association, Sammons Cancer Center, Dallas, TX 75246</wicri:regionArea></affiliation></author><author><name sortKey="Clark, J I" sort="Clark, J I" uniqKey="Clark J" first="J I" last="Clark">J I Clark</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL 60153, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL 60153</wicri:regionArea></affiliation></author><author><name sortKey="Lim, H Y" sort="Lim, H Y" uniqKey="Lim H" first="H Y" last="Lim">H Y Lim</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, Samsung Medical Center/Sungkyunkwan University, Seoul 135-710, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Internal Medicine, Samsung Medical Center/Sungkyunkwan University, Seoul 135-710</wicri:regionArea></affiliation></author><author><name sortKey="Porfiri, E" sort="Porfiri, E" uniqKey="Porfiri E" first="E" last="Porfiri">E. Porfiri</name><affiliation wicri:level="1"><nlm:affiliation>Queen Elizabeth Hospital Birmingham, Birmingham B15 2WB, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Queen Elizabeth Hospital Birmingham, Birmingham B15 2WB</wicri:regionArea></affiliation></author><author><name sortKey="Zalewski, P" sort="Zalewski, P" uniqKey="Zalewski P" first="P" last="Zalewski">P. Zalewski</name><affiliation wicri:level="1"><nlm:affiliation>Durham Regional Cancer Centre, Oshawa, Ontario L1G 2B9, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Durham Regional Cancer Centre, Oshawa, Ontario L1G 2B9</wicri:regionArea></affiliation></author><author><name sortKey="Kannourakis, G" sort="Kannourakis, G" uniqKey="Kannourakis G" first="G" last="Kannourakis">G. Kannourakis</name><affiliation wicri:level="1"><nlm:affiliation>Fiona Elsey Cancer Research Institute and Ballarat Oncology and Haematology Services, Ballarat, Victoria 3355, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Fiona Elsey Cancer Research Institute and Ballarat Oncology and Haematology Services, Ballarat, Victoria 3355</wicri:regionArea></affiliation></author><author><name sortKey="Staehler, M" sort="Staehler, M" uniqKey="Staehler M" first="M" last="Staehler">M. Staehler</name><affiliation wicri:level="1"><nlm:affiliation>Ludwig-Maximilians University of Munich, Munich 80539, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Ludwig-Maximilians University of Munich, Munich 80539</wicri:regionArea></affiliation></author><author><name sortKey="Tarazi, J" sort="Tarazi, J" uniqKey="Tarazi J" first="J" last="Tarazi">J. Tarazi</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Oncology, San Diego, CA 92121, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, San Diego, CA 92121</wicri:regionArea></affiliation></author><author><name sortKey="Rosbrook, B" sort="Rosbrook, B" uniqKey="Rosbrook B" first="B" last="Rosbrook">B. Rosbrook</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Oncology, San Diego, CA 92121, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, San Diego, CA 92121</wicri:regionArea></affiliation></author><author><name sortKey="Cisar, L" sort="Cisar, L" uniqKey="Cisar L" first="L" last="Cisar">L. Cisar</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Oncology, New York, NY 10017, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, New York, NY 10017</wicri:regionArea></affiliation></author><author><name sortKey="Hariharan, S" sort="Hariharan, S" uniqKey="Hariharan S" first="S" last="Hariharan">S. Hariharan</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Oncology, New York, NY 10017, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, New York, NY 10017</wicri:regionArea></affiliation></author><author><name sortKey="Kim, S" sort="Kim, S" uniqKey="Kim S" first="S" last="Kim">S. Kim</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Oncology, San Diego, CA 92121, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, San Diego, CA 92121</wicri:regionArea></affiliation></author><author><name sortKey="Rini, B I" sort="Rini, B I" uniqKey="Rini B" first="B I" last="Rini">B I Rini</name><affiliation wicri:level="1"><nlm:affiliation>Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195</wicri:regionArea></affiliation></author></analytic><series><title level="j">British journal of cancer</title><idno type="eISSN">1532-1827</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (adverse effects)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Carcinoma, Renal Cell (drug therapy)</term><term>Carcinoma, Renal Cell (mortality)</term><term>Carcinoma, Renal Cell (pathology)</term><term>Cytokines (therapeutic use)</term><term>Disease-Free Survival</term><term>Humans</term><term>Imidazoles (adverse effects)</term><term>Imidazoles (therapeutic use)</term><term>Indazoles (adverse effects)</term><term>Indazoles (therapeutic use)</term><term>Indoles (therapeutic use)</term><term>Kidney Neoplasms (drug therapy)</term><term>Kidney Neoplasms (mortality)</term><term>Kidney Neoplasms (pathology)</term><term>Niacinamide (adverse effects)</term><term>Niacinamide (analogs & derivatives)</term><term>Niacinamide (therapeutic use)</term><term>Phenylurea Compounds (adverse effects)</term><term>Phenylurea Compounds (therapeutic use)</term><term>Protein Kinase Inhibitors (adverse effects)</term><term>Protein Kinase Inhibitors (therapeutic use)</term><term>Pyrroles (therapeutic use)</term><term>Treatment Outcome</term><term>Tumor Burden</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antinéoplasiques (effets indésirables)</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Charge tumorale</term><term>Cytokines (usage thérapeutique)</term><term>Humains</term><term>Imidazoles (effets indésirables)</term><term>Imidazoles (usage thérapeutique)</term><term>Indazoles (effets indésirables)</term><term>Indazoles (usage thérapeutique)</term><term>Indoles (usage thérapeutique)</term><term>Inhibiteurs de protéines kinases (effets indésirables)</term><term>Inhibiteurs de protéines kinases (usage thérapeutique)</term><term>Nicotinamide (analogues et dérivés)</term><term>Nicotinamide (effets indésirables)</term><term>Nicotinamide (usage thérapeutique)</term><term>Néphrocarcinome (anatomopathologie)</term><term>Néphrocarcinome (mortalité)</term><term>Néphrocarcinome (traitement médicamenteux)</term><term>Phénylurées (effets indésirables)</term><term>Phénylurées (usage thérapeutique)</term><term>Pyrroles (usage thérapeutique)</term><term>Résultat thérapeutique</term><term>Survie sans rechute</term><term>Tumeurs du rein (anatomopathologie)</term><term>Tumeurs du rein (mortalité)</term><term>Tumeurs du rein (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term><term>Imidazoles</term><term>Indazoles</term><term>Niacinamide</term><term>Phenylurea Compounds</term><term>Protein Kinase Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Niacinamide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Cytokines</term><term>Imidazoles</term><term>Indazoles</term><term>Indoles</term><term>Niacinamide</term><term>Phenylurea Compounds</term><term>Protein Kinase Inhibitors</term><term>Pyrroles</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Nicotinamide</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Néphrocarcinome</term><term>Tumeurs du rein</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antinéoplasiques</term><term>Imidazoles</term><term>Indazoles</term><term>Inhibiteurs de protéines kinases</term><term>Nicotinamide</term><term>Phénylurées</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Néphrocarcinome</term><term>Tumeurs du rein</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Néphrocarcinome</term><term>Tumeurs du rein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Cytokines</term><term>Imidazoles</term><term>Indazoles</term><term>Indoles</term><term>Inhibiteurs de protéines kinases</term><term>Nicotinamide</term><term>Phénylurées</term><term>Pyrroles</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease-Free Survival</term><term>Humans</term><term>Treatment Outcome</term><term>Tumor Burden</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Charge tumorale</term><term>Humains</term><term>Résultat thérapeutique</term><term>Survie sans rechute</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the AXIS trial, axitinib prolonged progression-free survival (PFS) vs sorafenib in patients with advanced renal cell carcinoma (RCC) previously treated with sunitinib or cytokines.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24823696</PMID><DateCreated><Year>2014</Year><Month>06</Month><Day>12</Day></DateCreated><DateCompleted><Year>2014</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-1827</ISSN><JournalIssue CitedMedium="Internet"><Volume>110</Volume><Issue>12</Issue><PubDate><Year>2014</Year><Month>Jun</Month><Day>10</Day></PubDate></JournalIssue><Title>British journal of cancer</Title><ISOAbbreviation>Br. J. Cancer</ISOAbbreviation></Journal><ArticleTitle>Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.</ArticleTitle><Pagination><MedlinePgn>2821-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2014.244</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In the AXIS trial, axitinib prolonged progression-free survival (PFS) vs sorafenib in patients with advanced renal cell carcinoma (RCC) previously treated with sunitinib or cytokines.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In post hoc analyses, patients were grouped by objective response to prior therapy (yes vs no), prior therapy duration (< vs ⩾median), and tumour burden (baseline sum of the longest diameter < vs ⩾median). PFS and overall survival (OS), and safety by type and duration of prior therapy were evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Response to prior therapy did not influence outcome with second-line axitinib or sorafenib. PFS was significantly longer in axitinib-treated patients who received longer prior cytokine treatment and sorafenib-treated patients with smaller tumour burden following sunitinib. Overall survival with the second-line therapy was longer in patients who received longer duration of prior therapy, although not significant in the sunitinib-to-axitinib sequence subgroup; OS was also longer in patients with smaller tumour burden, but not significant in the cytokine-to-axitinib sequence subgroup. Safety profiles differed modestly by type and duration of prior therapy.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">AXIS data suggest that longer duration of the first-line therapy generally yields better outcome with the second-line therapy and that lack of response to first-line therapy does not preclude positive clinical outcomes with a second-line vascular endothelial growth factor-targeted agent in patients with advanced RCC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Escudier</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institut Gustave Roussy/Medical Oncology Department, Villejuif 94805, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michaelson</LastName><ForeName>M D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Motzer</LastName><ForeName>R J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hutson</LastName><ForeName>T E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Baylor-Sammons/Texas Oncology Physician's Association, Sammons Cancer Center, Dallas, TX 75246, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>J I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Department of Medicine, Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL 60153, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>H Y</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Samsung Medical Center/Sungkyunkwan University, Seoul 135-710, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porfiri</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Queen Elizabeth Hospital Birmingham, Birmingham B15 2WB, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zalewski</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Durham Regional Cancer Centre, Oshawa, Ontario L1G 2B9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kannourakis</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Fiona Elsey Cancer Research Institute and Ballarat Oncology and Haematology Services, Ballarat, Victoria 3355, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staehler</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ludwig-Maximilians University of Munich, Munich 80539, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarazi</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pfizer Oncology, San Diego, CA 92121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosbrook</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Pfizer Oncology, San Diego, CA 92121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cisar</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pfizer Oncology, New York, NY 10017, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hariharan</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pfizer Oncology, New York, NY 10017, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pfizer Oncology, San Diego, CA 92121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rini</LastName><ForeName>B I</ForeName><Initials>BI</Initials><AffiliationInfo><Affiliation>Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00678392</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Cancer</MedlineTA><NlmUniqueID>0370635</NlmUniqueID><ISSNLinking>0007-0920</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007191">Indazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010671">Phenylurea Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance></Chemical><Chemical><RegistryNumber>25X51I8RD4</RegistryNumber><NameOfSubstance UI="D009536">Niacinamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>9ZOQ3TZI87</RegistryNumber><NameOfSubstance UI="C471405">sorafenib</NameOfSubstance></Chemical><Chemical><RegistryNumber>C9LVQ0YUXG</RegistryNumber><NameOfSubstance UI="C503983">axitinib</NameOfSubstance></Chemical><Chemical><RegistryNumber>V99T50803M</RegistryNumber><NameOfSubstance UI="C473478">sunitinib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Invest New Drugs. 2012 Oct;30(5):2066-79</RefSource><PMID Version="1">22327313</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2012 May;48(7):1023-30</RefSource><PMID Version="1">22436979</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BJU Int. 2012 Dec;110(11):1747-53</RefSource><PMID Version="1">23106948</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2013 Apr 30;108(8):1571-8</RefSource><PMID Version="1">23579211</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 May;14(6):552-62</RefSource><PMID Version="1">23598172</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Target Oncol. 2013 Sep;8(3):203-9</RefSource><PMID Version="1">23300029</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2013 Dec;64(6):994-1002</RefSource><PMID Version="1">23219086</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2014 Mar 10;32(8):760-7</RefSource><PMID Version="1">24297950</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2000 Feb 2;92(3):205-16</RefSource><PMID Version="1">10655437</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Semin Radiat Oncol. 2003 Jul;13(3):176-81</RefSource><PMID Version="1">12903007</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2007 Jan 11;356(2):125-34</RefSource><PMID Version="1">17215530</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2011 Feb 1;104(3):399-406</RefSource><PMID Version="1">21285971</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Compr Canc Netw. 2011 Feb;9 Suppl 1:S1-29</RefSource><PMID Version="1">21335444</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2011 Mar 15;117(6):1183-9</RefSource><PMID Version="1">20960527</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2011 Dec 3;378(9807):1931-9</RefSource><PMID Version="1">22056247</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2012 Feb;61(2):307-16</RefSource><PMID Version="1">22055147</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2012 Oct;23 Suppl 7:vii65-71</RefSource><PMID Version="1">22997456</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002292" MajorTopicYN="N">Carcinoma, Renal Cell</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007191" MajorTopicYN="N">Indazoles</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007680" MajorTopicYN="N">Kidney Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009536" MajorTopicYN="N">Niacinamide</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010671" MajorTopicYN="N">Phenylurea Compounds</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011758" MajorTopicYN="N">Pyrroles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4056058</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>02</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>04</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>04</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24823696</ArticleId><ArticleId IdType="pii">bjc2014244</ArticleId><ArticleId IdType="doi">10.1038/bjc.2014.244</ArticleId><ArticleId IdType="pmc">PMC4056058</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003627 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003627 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:24823696
|texte= Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:24823696" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |